Abstract
Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.
Keywords: Breast cancer, proteome, RPPA, molecular technology, genomic profiling, reverse phase protein lysate arrays(RPPA), mass spectrometry, human genome, Epidermal Growth Factor Receptor (EGFR), genomic technologies.
Current Drug Targets
Title:Proteomic Classification of Breast Cancer
Volume: 13 Issue: 12
Author(s): Dalia Kamel, Bernadette Brady, Adel Tabchy, Gordon B. Mills and Bryan Hennessy
Affiliation:
Keywords: Breast cancer, proteome, RPPA, molecular technology, genomic profiling, reverse phase protein lysate arrays(RPPA), mass spectrometry, human genome, Epidermal Growth Factor Receptor (EGFR), genomic technologies.
Abstract: Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.
Export Options
About this article
Cite this article as:
Kamel Dalia, Brady Bernadette, Tabchy Adel, B. Mills Gordon and Hennessy Bryan, Proteomic Classification of Breast Cancer, Current Drug Targets 2012; 13 (12) . https://dx.doi.org/10.2174/138945012803530080
DOI https://dx.doi.org/10.2174/138945012803530080 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Mesothelin in Tumor Progression and Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Angiogenic and Anti-Angiogenic Therapy for Gastrointestinal Ulcers: New Challenges for Rational Therapeutic Predictions and Drug Design
Current Pharmaceutical Design Biomedical Applications of Gold Nanoparticles
Current Topics in Medicinal Chemistry Natural Compounds A Weapon to Ameliorate Breast Cancer Cells: A Review
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Colon and Rectal Cancer - Novel Biomarkers from Diagnosis to Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Tyrosine Kinase Inhibitors
Current Cancer Drug Targets The Antitumor Effects of Icaritin Against Breast Cancer is Related to Estrogen Receptors
Current Molecular Medicine Role of Liprins in the Regulation of Tumor Cell Motility and Invasion
Current Cancer Drug Targets Evaluation of <sup>177</sup>Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy
Current Radiopharmaceuticals <I>In Silico</I> and <I>In Vitro</I> Studies of Natural Compounds as Human CK2 Inhibitors
Current Computer-Aided Drug Design miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to Overcome Drug Resistance in Cancer
Current Drug Targets Risk Factors for Serious Adverse Effects of Thiopurines in Patients with Crohn’s Disease
Current Drug Safety Cholesterol: A Prelate in Cell Nucleus and its Serendipity
Current Molecular Medicine Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients
Current Cancer Drug Targets Polysaccharide-Based Materials Associated with or Coordinated to Gold Nanoparticles: Synthesis and Medical Application
Current Medicinal Chemistry A Facile and Microwave-assisted Rapid Synthesis of 2-Arylamino-4-(3′-indolyl)- thiazoles as Apoptosis Inducing Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Recent Clinical Evidence in Bisphosphonate-related Osteomyelitis of the Jaw: Focus on Risk, Prevention and Treatment
Reviews on Recent Clinical Trials Prodrug Design Targeting Intestinal PepT1 for Improved Oral Absorption: Design and Performance
Current Drug Metabolism Use of Nanoparticles as Therapy for Methicillin-Resistant Staphylococcus aureus Infections
Current Drug Metabolism